AstraZeneca (AZN) stock surged early Thursday after the pharma company reported core earnings of $2.09 per share on $14.89 billion in fourth-quarter sales.
↑ X NOW PLAYING How To Buy Stocks: IBD's Four Pillars Of InvestingBoth measures beat expectations, according to FactSet. Earnings rocketed 44% on a strict, as-reported basis, while sales climbed 24%.
For the year, AstraZeneca guided to sales growth in the high single-digit percentage range. The company also projects core earnings growth at a low double-digit percentage. Wall Street projected earnings of $9.27 per share on $56.79 billion in sales.
In premarket trades on the stock market today, AstraZeneca stock jumped more than 4.5% to 74.17.
More to follow.
YOU MAY ALSO LIKE:
GSK Surges 7% After Bumping Its 2031 Outlook To North Of $50 Billion
Merck Stock Plummets 9% As Gardasil Dynamics, 2025 Guidance Weigh On Shares
Looking For The Next Apple Or Amazon? Start With These S&P 500-Beating Lists
Want More IBD Insights? Subscribe To Our Investing Podcast!
Get Timely Buy & Sell Alerts With IBD Leaderboard
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.